Testosterone Science

Cancer

Sexual Function After Prostatectomy Improved by TRT

Specific Claim Evaluated

Testosterone cypionate 100 mg weekly for 12 weeks increased sexual activity by 0.91 daily events over placebo in men with hypogonadism after prostatectomy for low-grade cancer, with no biochemical recurrence and erythrocytosis only in the testosterone group.

Primary Research Supporting or Contradicting the Claim

The SPIRIT trial reported a between-group difference in sexual activity of 0.91 daily events, no biochemical recurrence, no change in erectile function and a duration insufficient to assess clinical recurrence (Bhasin et al., 2026).

Corrected Evidence-Based Interpretation

The report is correct.

Rationale for Grade

The article reports the effect size, the null erectile function result, the adverse events and the single-site limitation for physical performance testing. All figures match the published trial.

References

  1. Bhasin S, Burnett AL, Gagliano-Jucá T, Storer TW, Reid KF, Shang YV, Privat F, Chandra MS, Weiss M, Memish-Beleva Y, Lam H, Kibel AS, Pencina KM. Testosterone treatment in prostate cancer survivors with hypogonadism: a randomized clinical trial. JAMA Intern Med. 2026;186(7):805-814. PMID
    Supporting excerpt: "The trial was neither long enough nor large enough to evaluate clinical recurrence"

Post a Comment

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.